View ValuationEnzymatica 将来の成長Future 基準チェック /06現在、 Enzymaticaの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長37.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Breakeven Date Change • Jul 22No longer forecast to breakevenThe 2 analysts covering Enzymatica no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr12.3m in 2026. New consensus forecast suggests the company will make a loss of kr46.2m in 2026.Major Estimate Revision • Jun 16Consensus EPS estimates fall by 21%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from kr63.2m to kr65.0m. Forecast EPS reduced from -kr0.253 to -kr0.306 per share. Pharmaceuticals industry in Sweden expected to see average net income growth of 21% next year. Consensus price target broadly unchanged at kr4.34. Share price fell 3.5% to kr2.72 over the past week.Major Estimate Revision • May 02Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr78.1m to kr65.5m. Forecast losses increased from -kr0.186 to -kr0.262 per share. Pharmaceuticals industry in Sweden expected to see average net income growth of 9.6% next year. Consensus price target down from kr5.02 to kr4.44. Share price fell 6.5% to kr3.03 over the past week.Breakeven Date Change • May 02Forecast to breakeven in 2026The 2 analysts covering Enzymatica expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 29% per year to 2025. The company is expected to make a profit of kr12.6m in 2026. Average annual earnings growth of 76% is required to achieve expected profit on schedule.Breakeven Date Change • Mar 26No longer forecast to breakevenThe 2 analysts covering Enzymatica no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr22.6m in 2025. New consensus forecast suggests the company will make a loss of kr849.6k in 2025.Major Estimate Revision • Nov 14Consensus revenue estimates decrease by 30%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from kr76.3m to kr53.0m. EPS estimate unchanged from -kr0.15 per share at last update. Pharmaceuticals industry in Sweden expected to see average net income growth of 27% next year. Consensus price target down from kr5.63 to kr5.15. Share price fell 2.1% to kr3.32 over the past week.すべての更新を表示Recent updatesお知らせ • Jun 24Enzymatica AB (publ) Provides Update On The Evidence Base For Coldzyme And PLOS ONE Expression Of Concern Regarding Berlin II ArticleEnzymatica AB (publ) noted that the scientific journal PLOS ONE has published an Expression of Concern regarding an article on the Berlin II study from 2023. The notice is not a retraction. The article remains published. The scientific evidence base for ColdZyme – including the independent Davison study from 2025 – remains unchanged. The same applies to the regulatory position. PLOS notice concerns how certain exploratory analyses and wording were presented in the 2023 Berlin II article, rather than the conduct of the study or the validity of the underlying data. The primary endpoint in Berlin II was not met – as clearly stated in the published article. Nevertheless, the study included 438 randomized participants, of whom 220 were in the ColdZyme group, and contributes important safety and tolerability data in a large population. Davison et al. (2025), conducted at the University of Kent, is an independent, randomized and peer-reviewed clinical study that demonstrated statistically significant effects across several key endpoints related to upper respiratory tract infections. The Davison study is not affected by PLOS ONE’s questions regarding the Berlin II article. Enzymatica’s marketing claims for ColdZyme are based on a broader scientific foundation than the Berlin II article from 2023, including preclinical research, mechanistic data and several clinical studies, including Davison 2025. At present, PLOS ONE’s notice does not prompt any changes to the company’s marketing, clinical evaluation report (CER), Summary of Safety and Clinical Performance (SSCP), or regulatory status. ColdZyme is a clinically documented medical device mouth spray for colds and cold-like symptoms and is certified under the EU regulatory framework for medical devices, MDR Class III. The product was recently named best in test among cold sprays by the independent Swedish consumer guide Bäst-i-Test.se. An Expression of Concern is an editorial tool used by scientific journals to signal that a question has arisen regarding an article, without retracting the article. The article remains published and citable.お知らせ • Jun 09Enzymatica AB Announces Appointment of Joakim Tingström Nordin as Nordic Marketing and Sales Director, Effective August 2026Enzymatica AB had appointed Joakim Tingström Nordin as its new Nordic Marketing and Sales Director. He will assume the role in August and will be responsible for driving ColdZyme’s commercial development and growth across the Nordic region. Joakim Tingström Nordin brings more than 15 years of experience from the consumer healthcare industry and most recently joins from Karo Healthcare, where he held senior roles in marketing, sales, and commercial development across international markets. He has previously also worked at Haleon, GSK, and Novartis. As part of his role, Joakim will also join Enzymatica’s executive management team. Following Anna Söderlund's decision earlier this year to leave Enzymatica as Senior Director, Marketing & Sales Sweden, the organization has been reviewed, and the role has been expanded to include full Nordic responsibility. Joakim Tingström Nordin's initial focus will be to strengthen ColdZyme's visibility and availability ahead of the upcoming cold season. This includes increased distribution, stronger presence in pharmacies and e-commerce, enhanced product communication, and a more data-driven approach to ratings, reviews, and sampling.Reported Earnings • Apr 30First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: kr11.4m (down 6.8% from 1Q 2025). Net loss: kr13.5m (loss narrowed 25% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Apr 07Senior Director of Marketing & Sales recently sold kr120k worth of stockOn the 31st of March, Anna Soderlund sold around 40k shares on-market at roughly kr3.00 per share. This transaction amounted to 67% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr461k more than they sold in the last 12 months.Reported Earnings • Feb 19Full year 2025 earnings released: kr0.21 loss per share (vs kr0.28 loss in FY 2024)Full year 2025 results: kr0.21 loss per share (improved from kr0.28 loss in FY 2024). Revenue: kr53.9m (up 18% from FY 2024). Net loss: kr51.9m (loss narrowed 2.4% from FY 2024). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.お知らせ • Feb 19Enzymatica AB (publ), Annual General Meeting, May 07, 2026Enzymatica AB (publ), Annual General Meeting, May 07, 2026, at 14:30 W. Europe Standard Time. Location: lund. SwedenNew Risk • Feb 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr62m free cash flow). Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (kr449.1m market cap, or US$49.9m).分析記事 • Dec 20Will Enzymatica (STO:ENZY) Spend Its Cash Wisely?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...お知らせ • Dec 13Enzymatica AB (Publ) Announces CFO ChangesEnzymatica AB (publ) announced the appointment of Kristina Rylander as Acting CFO during a transition period in the spring of 2026. She will assume the role on 1 March 2026, following the departure of the current CFO, Therese Filmersson, as previously communicated. Kristina will be responsible for Enzymatica's finance function until Holger Lembrér assumes his position as the new permanent CFO, no later than 13 April 2026. Kristina Rylander has, for an extended period, served as a consultant to Enzymatica, which has provided her with insight into the company's operations and processes. In her role as Acting CFO, she will ensure continuity in Enzymatica's financial reporting, internal processes, and ongoing projects.Reported Earnings • Nov 02Third quarter 2025 earnings released: kr0.035 loss per share (vs kr0.039 loss in 3Q 2024)Third quarter 2025 results: kr0.035 loss per share. Revenue: kr15.0m (up 19% from 3Q 2024). Net loss: kr8.40m (loss widened 16% from 3Q 2024).お知らせ • Oct 14Enzymatica Expands the ColdZyme Range with A New Flavor - EucalyptusEnzymatica expands the ColdZyme range with a new flavour - Eucalyptus. The new flavour offers the same barrier technology and clinically proven benefit against common cold viruses, now with a fresh and cooling taste experience. Like other products in the series, ColdZyme Eucalyptus creates a protective barrier in the throat that helps reduce the viral load, shorten the duration of a cold, and relieve symptoms. The ColdZyme range previously included menthol and strawberry flavours - with Eucalyptus now introduced as a fresh, cooling alternative. The launch of ColdZymeEucalyptus will take place in October in Sweden. The product will be available in pharmacies and online. ColdZyme has been shown in peer-reviewed studies to reduce viral load by up to 94% and shorten the duration of a cold by an average of 40%.お知らせ • Oct 13Enzymatica AB (Publ) Appoints Holger Lembrér as CFO, Effective April 2026Enzymatica AB (publ) has appointed Holger Lembrér as new Chief Financial Officer (CFO). He will assume the position no later than April 2026 and will be part of the company's executive management team. Holger Lembrér brings extensive experience as CFO and finance executive from international and publicly listed companies, primarily within the MedTech, Pharma and industrial sectors. He most recently served as CFO at Boule Diagnostics, where he held overall responsibility for the Group's finance function. Prior to that, Holger was CFO at Oncopeptides and held several senior positions within ASSA ABLOY, including CFO for the Senior Care business area and Investor Relations Officer at Group level. He began his career as an auditor at EY.お知らせ • Oct 03+ 2 more updatesEnzymatica AB (publ) to Report First Half, 2026 Results on Jul 16, 2026Enzymatica AB (publ) announced that they will report first half, 2026 results on Jul 16, 2026Recent Insider Transactions • Sep 22Director recently bought kr544k worth of stockOn the 18th of September, Mats Andersson bought around 230k shares on-market at roughly kr2.36 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr970k more in shares than they have sold in the last 12 months.お知らせ • Aug 22Enzymatica AB (Publ) Appoints Claus Egstrand as Member of Board of DirectorsEnzymatica AB (publ) on 22 August 2025 held an Extraordinary General Meeting approved Claus Egstrand was elected as an ordinary member of the Board of Directors for the period until the end of the next Annual General Meeting.お知らせ • Aug 13Enzymatica AB (Publ) Announces Chief Executive Officer ChangesThe Board of Directors of Enzymatica AB (publ) has appointed Sana Alajmovic as the new Chief Executive Officer. She succeeds Claus Egstrand, who has announced that he is stepping down from his operational role, but he will be proposed to join the company's Board of Directors in order to ensure continuity. Sana Alajmovic is the co-founder and current CEO of Sigrid Therapeutics. She brings extensive experience from business development and leadership within the life science sector, with a strong track record in commercializing research and developing strategic partnerships with international pharmaceutical and consumer health companies. Known for her strategic thinking and dynamic, empathetic leadership, she has established herself as a pioneer in the industry. Sana Alajmovic has received several awards for her entrepreneurship and leadership, including Sweden's Most Important Female Founder by Dagens Industri in 2021 and Female Leader of the Future by Ledarna in both 2020 and 2021. She has also been named one of the world's top life science innovators under the age of 40. Sana Alajmovic will assume her new role no later than 31 January 2026.Reported Earnings • Jul 18Second quarter 2025 earnings released: kr0.06 loss per share (vs kr0.08 loss in 2Q 2024)Second quarter 2025 results: kr0.06 loss per share. Revenue: kr8.28m (up 29% from 2Q 2024). Net loss: kr14.5m (loss widened 4.8% from 2Q 2024).分析記事 • Jul 01Is Enzymatica (STO:ENZY) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...お知らせ • Jun 30Enzymatica AB (Publ) Announces Step Down of Therese Filmersson as CFOEnzymatica AB (publ) announced that the company's Chief Financial Officer (CFO), Therese Filmersson, has decided to leave her position. The decision has been made in mutual agreement between Therese Filmersson and the company's Board of Directors. Therese Filmersson will remain in her role during the notice period to ensure a smooth transition. The recruitment process to find her successor has been initiated.お知らせ • Jun 26+ 1 more updateEnzymatica AB (publ) Announces Appointment of Claus Egstrand to the BoardThe CEO of Enzymatica AB, Claus Egstrand, is stepping down from his role and will join the company's Board of Directors. Recruitment of a new CEO has begun. The change will ensure long-term stability in the company's leadership as it prepares for international expansion. Following the publication of the strong research results for ColdZyme in The Journal of Physiology in February this year, efforts have intensified to sign international distribution agreements. In order to ensure longer term continuity in these discussions and partnerships, Claus Egstrand has decided to step down from his position as CEO of Enzymatica. The Nomination Committee of Enzymatica intends to propose Claus Egstrand as a new member of the company's Board of Directors. The proposal will be presented at an Extraordinary General Meeting and it already has the support of a clear majority of shareholders.お知らせ • Jun 21Enzymatica AB (publ) to Report Fiscal Year 2025 Final Results on Apr 14, 2026Enzymatica AB (publ) announced that they will report fiscal year 2025 final results on Apr 14, 2026New Risk • May 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr62m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr62m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr48m revenue, or US$5.0m). Market cap is less than US$100m (kr708.8m market cap, or US$72.7m).Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Moa Fransson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 16Full year 2024 earnings released: kr0.28 loss per share (vs kr0.30 loss in FY 2023)Full year 2024 results: kr0.28 loss per share. Revenue: kr45.6m (down 11% from FY 2023). Net loss: kr53.2m (loss widened 6.9% from FY 2023).お知らせ • Apr 03Enzymatica AB (publ), Annual General Meeting, May 07, 2025Enzymatica AB (publ), Annual General Meeting, May 07, 2025, at 14:30 W. Europe Standard Time. Location: elite hotel ideon, scheelevagen 27, lund SwedenNew Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr61m free cash flow). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (48% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (kr46m revenue, or US$4.2m). Market cap is less than US$100m (kr356.8m market cap, or US$33.3m).Reported Earnings • Feb 19Full year 2024 earnings released: kr0.25 loss per share (vs kr0.30 loss in FY 2023)Full year 2024 results: kr0.25 loss per share. Revenue: kr45.6m (down 11% from FY 2023). Net loss: kr53.2m (loss widened 6.9% from FY 2023).お知らせ • Feb 18Enzymatica AB (publ) to Report Fiscal Year 2025 Results on Feb 18, 2026Enzymatica AB (publ) announced that they will report fiscal year 2025 results on Feb 18, 2026New Risk • Jan 23New major risk - Revenue and earnings growthEarnings have declined by 17% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr44m revenue, or US$4.0m). Market cap is less than US$100m (kr321.5m market cap, or US$29.2m).New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr52m net loss in 2 years). Revenue is less than US$5m (kr44m revenue, or US$4.0m). Market cap is less than US$100m (kr353.9m market cap, or US$31.7m).お知らせ • Jan 09Enzymatica AB Appoints Anna Söderlund as Senior Director Marketing & SalesEnzymatica AB (publ) announced that Anna Söderlund has joined as the new Senior Director Marketing & Sales. With over 25 years of experience in the Life Science industry, where she has held leading roles at global companies such as Pfizer and MSD, Anna brings solid expertise to the company. Anna Söderlund holds a Master of Science in Economics from Linköping University and has previously successfully worked in key roles in marketing, sales and business development. The recruitment of Anna Söderlund strengthens Enzymatica's commitment to further expand and establish itself as a leading player in its segment. Anna Söderlund has taken up her position and is part of Enzymatica's Group Management.Recent Insider Transactions • Nov 17Independent Director recently bought kr93k worth of stockOn the 11th of November, Louise Nicolin bought around 51k shares on-market at roughly kr1.84 per share. This transaction amounted to 51% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr117k. Despite this recent purchase, insiders have collectively sold kr1.4m more in shares than they bought in the last 12 months.Reported Earnings • Nov 08Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: kr12.6m (down 5.3% from 3Q 2023). Net loss: kr7.25m (loss narrowed 22% from 3Q 2023). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 32% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.お知らせ • Nov 07+ 3 more updatesEnzymatica AB (publ) to Report Fiscal Year 2024 Results on Apr 10, 2025Enzymatica AB (publ) announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on Apr 10, 2025Recent Insider Transactions • Sep 25Independent Chairman recently bought kr117k worth of stockOn the 16th of September, Bengt Baron bought around 45k shares on-market at roughly kr2.60 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Bengt has been a buyer over the last 12 months, purchasing a net total of kr681k worth in shares.Recent Insider Transactions • Sep 23Independent Chairman recently bought kr117k worth of stockOn the 16th of September, Bengt Baron bought around 45k shares on-market at roughly kr2.60 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Bengt has been a buyer over the last 12 months, purchasing a net total of kr681k worth in shares.お知らせ • Aug 17Enzymatica AB (publ) Announces Final Results from Independent Clinical Study of Coldzyme Show Duration of Illness Lowered by Approximately 5 DaysEnzymatica AB announced that the University of Kent has published final results for the Primary Endpoint from the now completed double-blind, placebo-controlled, randomized trial. The study now completed is an independent, investigator initiated in vivo study led by Glen Davison, professor of sports and exercise science and researcher in exercise immunology at the University of Kent, in England. ColdZyme directly forms a physical barrier in the mouth and throat that coats, moisturizes and protects the oral cavity and throat, trapping viruses and inactivating and inhibiting the ability of trapped viruses to infect cells and reproduce. The over-the-counter mouth spray has been certified according to the EU regulation MDR (class III) by Eurofins, an approved European control body for medical devices. The certification entails stricter requirements for the evidence of clinical validity, safe design and market surveillance. ColdZyme products are now MDR certified with the following expanded intended uses: Treat and relieve cold and flu-like symptoms. and with the following extended product claims: Protects against viruses that cause cold and flu-like infections in the upper respiratory tract. Shortens the duration of cold and flu-like infections of the upper respiratory tract if used at an early stage of the infection. Relieves cold and flu-like symptoms, including sore throat.New Risk • Aug 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr16m net loss in 2 years). Shareholders have been diluted in the past year (5.6% increase in shares outstanding). Revenue is less than US$5m (kr45m revenue, or US$4.3m). Market cap is less than US$100m (kr324.2m market cap, or US$30.7m).New Risk • Jul 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr56m Forecast net loss in 2 years: kr16m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr16m net loss in 2 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (5.6% increase in shares outstanding). Significant insider selling over the past 3 months (kr645k sold). Revenue is less than US$5m (kr45m revenue, or US$4.2m). Market cap is less than US$100m (kr346.8m market cap, or US$32.5m).Breakeven Date Change • Jul 22No longer forecast to breakevenThe 2 analysts covering Enzymatica no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr12.3m in 2026. New consensus forecast suggests the company will make a loss of kr46.2m in 2026.お知らせ • Jul 20Enzymatica AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 131.770487 million.Enzymatica AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 131.770487 million. Security Name: Shares Security Type: Common Stock Securities Offered: 69,352,888 Price\Range: SEK 1.9 Transaction Features: Rights Offering分析記事 • Jul 20Is Enzymatica (STO:ENZY) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Jul 19Second quarter 2024 earnings released: kr0.08 loss per share (vs kr0.07 loss in 2Q 2023)Second quarter 2024 results: kr0.08 loss per share (further deteriorated from kr0.07 loss in 2Q 2023). Revenue: kr6.43m (down 27% from 2Q 2023). Net loss: kr13.8m (loss widened 20% from 2Q 2023). Revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 38% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.Recent Insider Transactions • Jun 21Independent Director recently bought kr4.6m worth of stockOn the 13th of June, Gudmundur Palmason bought around 2m shares on-market at roughly kr2.98 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr4.4m more in shares than they have sold in the last 12 months.Major Estimate Revision • Jun 16Consensus EPS estimates fall by 21%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from kr63.2m to kr65.0m. Forecast EPS reduced from -kr0.253 to -kr0.306 per share. Pharmaceuticals industry in Sweden expected to see average net income growth of 21% next year. Consensus price target broadly unchanged at kr4.34. Share price fell 3.5% to kr2.72 over the past week.お知らせ • Jun 15Enzymatica AB (Publ) Announces Interim Results from Independent Clinical Study of Coldzyme® Show Duration of Illness Lowered by Approximately 5 DaysEnzymatica AB announced that University of Kent has earlier this afternoon published interim results from the ongoing double-blind, placebo-controlled, randomized on the effects of ColdZyme and the product's effect on treating the symptoms and duration of Upper Respiratory Tract Infections (URTI). Interim results have showed that Enzymatica's ColdZyme oral spray reduces the amount of rhinovirus and reduces the number of sick days by approximately five days, with number of sick days being the primary endpoint of the study. The study is an independent, investigator-initiated in vivo study led by Glen Davison, professor of sports and exercise science and researcher in exercise immunology at the University of Kent, in England. Glen Davison researches the effects of training and exercise on the immune system and the body's resistance to infections. The main focus is evaluating products and measures that can help prevent upper respiratory tract infections, such as the common cold. Glen Davison and his research team have been studying the effects of Cold Zyme since 2017 and published the first study four years ago. The study is investigator-initiated, prospective, double-blind, placebo- controlled, and randomized. The study includes roughly 160 athletes in endurance sports, divided into two groups, where one received ColdZyme and the other a placebo. The participants have kept a training diary and filled in a daily questionnaire about symptoms in the upper respiratory tract. When participants experienced symptoms, they took throat samples and began using the mouth spray as instructed. ColdZyme directly forms a physical barrier in the mouth and throat that coats, moisturizes and protects the oral cavity and throat, trapping viruses and inactivating and inhibiting the ability of trapped viruses to infect cells and reproduce. The over-the-counter mouth spray has been certified according to the EU regulation MDR (class III) by Eurofins, an approved European control body for medical devices. The certification entails stricter requirements for the evidence of clinical validity, safe design and market surveillance. ColdZyme products are now MDR certified with the following expanded intended uses: Treat and relieve cold and flu-like symptoms. and with the following extended product claims: Protects against viruses that cause cold and flu-like infections in the upper respiratory tract. Shortens the duration of cold and flu-like infections of the upper respiratory tract if used at an early stage of the infection. Relieves cold and flu-like symptoms, including sore throat.Major Estimate Revision • May 02Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr78.1m to kr65.5m. Forecast losses increased from -kr0.186 to -kr0.262 per share. Pharmaceuticals industry in Sweden expected to see average net income growth of 9.6% next year. Consensus price target down from kr5.02 to kr4.44. Share price fell 6.5% to kr3.03 over the past week.Breakeven Date Change • May 02Forecast to breakeven in 2026The 2 analysts covering Enzymatica expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 29% per year to 2025. The company is expected to make a profit of kr12.6m in 2026. Average annual earnings growth of 76% is required to achieve expected profit on schedule.New Risk • Apr 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr36m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr36m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr24m net loss in 2 years). Shareholders have been diluted in the past year (5.6% increase in shares outstanding). Significant insider selling over the past 3 months (kr960k sold). Revenue is less than US$5m (kr47m revenue, or US$4.3m). Market cap is less than US$100m (kr504.5m market cap, or US$46.1m).Reported Earnings • Apr 26First quarter 2024 earnings released: kr0.11 loss per share (vs kr0.091 loss in 1Q 2023)First quarter 2024 results: kr0.11 loss per share (further deteriorated from kr0.091 loss in 1Q 2023). Revenue: kr9.42m (down 28% from 1Q 2023). Net loss: kr18.9m (loss widened 26% from 1Q 2023). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.New Risk • Apr 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr15m net loss in 3 years). Shareholders have been diluted in the past year (5.6% increase in shares outstanding). Significant insider selling over the past 3 months (kr960k sold). Revenue is less than US$5m (kr51m revenue, or US$4.8m). Market cap is less than US$100m (kr599.9m market cap, or US$56.7m).Recent Insider Transactions • Mar 29Independent Director recently sold kr60k worth of stockOn the 25th of March, Gudmundur Palmason sold around 19k shares on-market at roughly kr3.14 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth kr900k. Despite this recent sale, insiders have collectively bought kr400k more than they sold in the last 12 months.お知らせ • Mar 28Enzymatica AB (publ) Announces Composition of Nomination CommitteeEnzymatica AB (publ) announced the nomination committee, in respect of the annual general meeting 2024, has been comprised of Mats Andersson (Abanico Invest AB as well as private holdings), Håkan Roos (Roosgruppen AB), Björn Algkvist (Fibonacci Growth Capital AB), Guðmundur Pálmason (Fortus hf.) and the chairman of the board, Bengt Baron. Björn Algkvist served as chairman of the Nomination Committee.New Risk • Mar 26New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: kr50m Forecast net loss in 3 years: kr15m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr15m net loss in 3 years). Significant insider selling over the past 3 months (kr900k sold). Revenue is less than US$5m (kr51m revenue, or US$4.8m). Market cap is less than US$100m (kr501.0m market cap, or US$47.5m).Breakeven Date Change • Mar 26No longer forecast to breakevenThe 2 analysts covering Enzymatica no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr22.6m in 2025. New consensus forecast suggests the company will make a loss of kr849.6k in 2025.お知らせ • Mar 15Enzymatica AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 27.37614 million.Enzymatica AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 27.37614 million. Security Name: Shares Security Type: Common Stock Securities Offered: 9,125,380 Price\Range: SEK 3 Transaction Features: Rights OfferingRecent Insider Transactions • Mar 03Independent Director recently sold kr900k worth of stockOn the 23rd of February, Gudmundur Palmason sold around 300k shares on-market at roughly kr3.00 per share. This transaction amounted to 3.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr390k more than they bought in the last 12 months.New Risk • Feb 19New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risks Revenue is less than US$5m (kr51m revenue, or US$4.9m). Market cap is less than US$100m (kr500.2m market cap, or US$48.0m).Reported Earnings • Feb 18Full year 2023 earnings released: kr0.30 loss per share (vs kr0.45 loss in FY 2022)Full year 2023 results: kr0.30 loss per share (improved from kr0.45 loss in FY 2022). Revenue: kr50.9m (up 4.0% from FY 2022). Net loss: kr49.7m (loss narrowed 28% from FY 2022). Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 16Enzymatica AB (publ) to Report Fiscal Year 2023 Final Results on Apr 09, 2024Enzymatica AB (publ) announced that they will report fiscal year 2023 final results at 9:00 AM, Central European Standard Time on Apr 09, 2024New Risk • Feb 08New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr65m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr65m free cash flow). Minor Risks Revenue is less than US$5m (kr52m revenue, or US$4.9m). Market cap is less than US$100m (kr553.5m market cap, or US$52.8m).お知らせ • Dec 07+ 4 more updatesEnzymatica AB (publ) to Report Q1, 2024 Results on Apr 25, 2024Enzymatica AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024Major Estimate Revision • Nov 14Consensus revenue estimates decrease by 30%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from kr76.3m to kr53.0m. EPS estimate unchanged from -kr0.15 per share at last update. Pharmaceuticals industry in Sweden expected to see average net income growth of 27% next year. Consensus price target down from kr5.63 to kr5.15. Share price fell 2.1% to kr3.32 over the past week.Reported Earnings • Nov 08Third quarter 2023 earnings released: kr0.056 loss per share (vs kr0.085 loss in 3Q 2022)Third quarter 2023 results: kr0.056 loss per share (improved from kr0.085 loss in 3Q 2022). Revenue: kr13.3m (down 28% from 3Q 2022). Net loss: kr9.24m (loss narrowed 29% from 3Q 2022). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.Recent Insider Transactions • Oct 02Independent Chairman recently bought kr564k worth of stockOn the 27th of September, Bengt Baron bought around 190k shares on-market at roughly kr2.97 per share. This transaction amounted to 5.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Bengt has been a buyer over the last 12 months, purchasing a net total of kr1.6m worth in shares.お知らせ • Sep 22Enzymatica AB (publ) Announces Interim Report from Clinical Study: ColdZyme Significantly Reduces Rhinovirus Viral Load and Symptoms of Sore ThroatEnzymatica AB (publ) announced that the first results from an ongoing independent clinical study at the University of Kent, UK, show that ColdZyme® significantly reduces the viral load of rhinovirus, the predominant cause of the common cold. Additionally, participants who used ColdZyme experienced significantly less severe sore throat symptoms than those who used placebo. The researchers are assessing the efficacy of ColdZyme mouth spray on upper respiratory tract infection (URTI) parameters, including viral load, in a randomized, double-blind, and placebo-controlled trial, under free-living conditions in endurance athletes (e.g. runners, cyclists, triathletes). The final study is expected to be published in 2024. The interim results have been submitted for presentation at a scientific conference, and are currently under review, hopefully for presentation early in 2024. The trial is investigator initiated, prospective, double-blind, placebo-controlled, and randomized. So far, it comprises 51 endurance athletes divided into two groups, one which received ColdZyme and the other placebo. Participants kept a training log and filled out a daily questionnaire on upper respiratory tract infection symptoms. When participants experienced symptoms, they were instructed to take self-swabs from their throat and start using the mouth spray according to instructions. The trial builds on a previous study in 2020 by the same research team, showing that ColdZyme reduces the duration and symptoms of common cold in endurance athletes. ColdZyme is a prescription free mouth spray that is sold in more than 30 markets on four continents. It is also marketed under brand names such as ViruProtect®, Physiomer®, Bisolviral® and ADerogyl®.お知らせ • Aug 23Enzymatica AB (publ) Announces New StudyEnzymatica AB (publ) announced new study: ColdZyme breaks the infection cycle, limiting the spread of viruses to more cells. The researchers believe that ColdZyme would have the same effect on other respiratory viruses. ColdZyme mouth spray is sold in more than 30 markets on four continents, also under brand names such as ViruProtect, Bisolviral and ADerogyl. Previous studies have shown how application of ColdZyme before infection blocks viruses from sticking to human cells. The new study shows that ColdZyme also reduces viral load and the virus's ability to spread in cell cultures that were already infected with virus (influenza A, H3N2). The research from the Medical University of Innsbruck shows a more than 99% lower viral load after only three treatments with ColdZyme, compared to infected cells that were treated with salt solution.分析記事 • Jul 22Is Enzymatica (STO:ENZY) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Jul 19Second quarter 2023 earnings released: kr0.07 loss per share (vs kr0.10 loss in 2Q 2022)Second quarter 2023 results: kr0.07 loss per share (improved from kr0.10 loss in 2Q 2022). Revenue: kr8.76m (down 8.9% from 2Q 2022). Net loss: kr11.5m (loss narrowed 25% from 2Q 2022). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings.Recent Insider Transactions • Jun 24Independent Director recently bought kr157k worth of stockOn the 16th of June, Louise Nicolin bought around 57k shares on-market at roughly kr2.75 per share. This transaction increased Louise's direct individual holding by 1x at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr414k. Despite this recent purchase, insiders have collectively sold kr575k more in shares than they bought in the last 12 months.Recent Insider Transactions • Jun 22Independent Director recently bought kr157k worth of stockOn the 16th of June, Louise Nicolin bought around 57k shares on-market at roughly kr2.75 per share. This transaction increased Louise's direct individual holding by 1x at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr414k. Despite this recent purchase, insiders have collectively sold kr575k more in shares than they bought in the last 12 months.Recent Insider Transactions • May 04Independent Chairman recently bought kr414k worth of stockOn the 28th of April, Bengt Baron bought around 160k shares on-market at roughly kr2.59 per share. This transaction amounted to 8.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth kr600k. Bengt has been a buyer over the last 12 months, purchasing a net total of kr1.0m worth in shares.Reported Earnings • Apr 30First quarter 2023 earnings released: kr0.091 loss per share (vs kr0.12 loss in 1Q 2022)First quarter 2023 results: kr0.091 loss per share (improved from kr0.12 loss in 1Q 2022). Revenue: kr13.0m (up 213% from 1Q 2022). Net loss: kr14.9m (loss narrowed 17% from 1Q 2022). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 32% per year, which means it has not declined as severely as earnings.Recent Insider Transactions • Mar 15Independent Director recently sold kr1.5m worth of stockOn the 9th of March, Gudmundur Palmason sold around 500k shares on-market at roughly kr3.00 per share. This transaction amounted to 5.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr1.2m more than they bought in the last 12 months.Breakeven Date Change • Mar 12Forecast to breakeven in 2025The 2 analysts covering Enzymatica expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 56% per year to 2024. The company is expected to make a profit of kr8.01m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.Major Estimate Revision • Feb 24Consensus revenue estimates decrease by 15%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from kr82.3m to kr69.9m. EPS estimate unchanged from -kr0.23 per share at last update. Pharmaceuticals industry in Sweden expected to see average net income growth of 14% next year. Consensus price target down from kr5.99 to kr5.71. Share price fell 16% to kr2.78 over the past week.Reported Earnings • Feb 19Full year 2022 earnings released: kr0.45 loss per share (vs kr0.31 loss in FY 2021)Full year 2022 results: kr0.45 loss per share (further deteriorated from kr0.31 loss in FY 2021). Revenue: kr48.9m (down 14% from FY 2021). Net loss: kr68.7m (loss widened 51% from FY 2021). Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.お知らせ • Feb 18Enzymatica AB (publ) to Report Fiscal Year 2023 Results on Feb 16, 2024Enzymatica AB (publ) announced that they will report fiscal year 2023 results on Feb 16, 2024分析記事 • Feb 18Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Jan 19+ 3 more updatesEnzymatica AB (publ) to Report Nine Months, 2023 Results on Nov 07, 2023Enzymatica AB (publ) announced that they will report nine months, 2023 results on Nov 07, 2023Breakeven Date Change • Nov 18No longer forecast to breakevenThe analyst covering Enzymatica no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr10.4m in 2023. New forecast suggests the company will make a loss of kr995.4k in 2024.Reported Earnings • Nov 03Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr18.5m (up 20% from 3Q 2021). Net loss: kr13.1m (loss widened 114% from 3Q 2021). Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 30% growth forecast for the Pharmaceuticals industry in Sweden.Major Estimate Revision • Jul 26Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from kr99.7m to kr86.1m. EPS estimate increased from -kr0.23 to -kr0.21 per share. Pharmaceuticals industry in Sweden expected to see average net income growth of 4.4% next year. Consensus price target down from kr9.64 to kr7.40. Share price was steady at kr5.50 over the past week.Reported Earnings • Jul 19Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr9.62m (up 57% from 2Q 2021). Net loss: kr15.4m (loss narrowed 22% from 2Q 2021). Over the next year, revenue is forecast to grow 188%, compared to a 97% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 5% per year.Breakeven Date Change • May 06Forecast breakeven date moved forward to 2022The 2 analysts covering Enzymatica previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr8.50m in 2022. Earnings growth of 97% is required to achieve expected profit on schedule. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Enzymatica は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OM:ENZY - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202653-47-39-39N/A12/31/202554-52-41-41N/A9/30/202553-54-62-62N/A6/30/202550-53-64-64N/A3/31/202548-52-62-62N/A12/31/202446-53-61-61N/A9/30/202444-54-43-43N/A6/30/202445-56-45-45N/A3/31/202447-54-36-35N/A12/31/202351-50-41-40N/A9/30/202352-58-65-65N/A6/30/202357-62-56-55N/A3/31/202358-66-69-67N/A12/31/202249-69-68-65N/A9/30/202251-57-49-44N/A6/30/202248-50-59-54N/A3/31/202244-55-51-47N/A12/31/202157-45-42-36N/A9/30/202181-35-46-38N/A6/30/202194-31-26-18N/A3/31/2021101-23-13-5N/A12/31/2020111-13-15-11N/A9/30/202091-18-4-3N/A6/30/202082-24-17-16N/A3/31/202075-28-27-27N/A12/31/201961-41N/A-38N/A9/30/201958-43N/A-36N/A6/30/201952-45N/A-38N/A3/31/201951-45N/A-43N/A12/31/201853-43N/A-29N/A9/30/201853-41N/A-29N/A6/30/201864-35N/A-25N/A3/31/201865-30N/A-15N/A12/31/201759-31N/A-23N/A9/30/201752-43N/A-27N/A6/30/201739-46N/A-35N/A3/31/201738-48N/A-42N/A12/31/201636-45N/A-38N/A9/30/201636-39N/A-48N/A6/30/201631-42N/A-45N/A3/31/201629-40N/A-38N/A12/31/201528-41N/A-38N/A9/30/201526-42N/A-39N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ENZYの予測収益成長が 貯蓄率 ( 2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: ENZYの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: ENZYの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: ENZYの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: ENZYの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ENZYの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/01 23:08終値2026/07/01 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Enzymatica AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Jakob LembkeABG Sundal Collier SponsoredGustaf MeyerRedeye
Breakeven Date Change • Jul 22No longer forecast to breakevenThe 2 analysts covering Enzymatica no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr12.3m in 2026. New consensus forecast suggests the company will make a loss of kr46.2m in 2026.
Major Estimate Revision • Jun 16Consensus EPS estimates fall by 21%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from kr63.2m to kr65.0m. Forecast EPS reduced from -kr0.253 to -kr0.306 per share. Pharmaceuticals industry in Sweden expected to see average net income growth of 21% next year. Consensus price target broadly unchanged at kr4.34. Share price fell 3.5% to kr2.72 over the past week.
Major Estimate Revision • May 02Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr78.1m to kr65.5m. Forecast losses increased from -kr0.186 to -kr0.262 per share. Pharmaceuticals industry in Sweden expected to see average net income growth of 9.6% next year. Consensus price target down from kr5.02 to kr4.44. Share price fell 6.5% to kr3.03 over the past week.
Breakeven Date Change • May 02Forecast to breakeven in 2026The 2 analysts covering Enzymatica expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 29% per year to 2025. The company is expected to make a profit of kr12.6m in 2026. Average annual earnings growth of 76% is required to achieve expected profit on schedule.
Breakeven Date Change • Mar 26No longer forecast to breakevenThe 2 analysts covering Enzymatica no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr22.6m in 2025. New consensus forecast suggests the company will make a loss of kr849.6k in 2025.
Major Estimate Revision • Nov 14Consensus revenue estimates decrease by 30%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from kr76.3m to kr53.0m. EPS estimate unchanged from -kr0.15 per share at last update. Pharmaceuticals industry in Sweden expected to see average net income growth of 27% next year. Consensus price target down from kr5.63 to kr5.15. Share price fell 2.1% to kr3.32 over the past week.
お知らせ • Jun 24Enzymatica AB (publ) Provides Update On The Evidence Base For Coldzyme And PLOS ONE Expression Of Concern Regarding Berlin II ArticleEnzymatica AB (publ) noted that the scientific journal PLOS ONE has published an Expression of Concern regarding an article on the Berlin II study from 2023. The notice is not a retraction. The article remains published. The scientific evidence base for ColdZyme – including the independent Davison study from 2025 – remains unchanged. The same applies to the regulatory position. PLOS notice concerns how certain exploratory analyses and wording were presented in the 2023 Berlin II article, rather than the conduct of the study or the validity of the underlying data. The primary endpoint in Berlin II was not met – as clearly stated in the published article. Nevertheless, the study included 438 randomized participants, of whom 220 were in the ColdZyme group, and contributes important safety and tolerability data in a large population. Davison et al. (2025), conducted at the University of Kent, is an independent, randomized and peer-reviewed clinical study that demonstrated statistically significant effects across several key endpoints related to upper respiratory tract infections. The Davison study is not affected by PLOS ONE’s questions regarding the Berlin II article. Enzymatica’s marketing claims for ColdZyme are based on a broader scientific foundation than the Berlin II article from 2023, including preclinical research, mechanistic data and several clinical studies, including Davison 2025. At present, PLOS ONE’s notice does not prompt any changes to the company’s marketing, clinical evaluation report (CER), Summary of Safety and Clinical Performance (SSCP), or regulatory status. ColdZyme is a clinically documented medical device mouth spray for colds and cold-like symptoms and is certified under the EU regulatory framework for medical devices, MDR Class III. The product was recently named best in test among cold sprays by the independent Swedish consumer guide Bäst-i-Test.se. An Expression of Concern is an editorial tool used by scientific journals to signal that a question has arisen regarding an article, without retracting the article. The article remains published and citable.
お知らせ • Jun 09Enzymatica AB Announces Appointment of Joakim Tingström Nordin as Nordic Marketing and Sales Director, Effective August 2026Enzymatica AB had appointed Joakim Tingström Nordin as its new Nordic Marketing and Sales Director. He will assume the role in August and will be responsible for driving ColdZyme’s commercial development and growth across the Nordic region. Joakim Tingström Nordin brings more than 15 years of experience from the consumer healthcare industry and most recently joins from Karo Healthcare, where he held senior roles in marketing, sales, and commercial development across international markets. He has previously also worked at Haleon, GSK, and Novartis. As part of his role, Joakim will also join Enzymatica’s executive management team. Following Anna Söderlund's decision earlier this year to leave Enzymatica as Senior Director, Marketing & Sales Sweden, the organization has been reviewed, and the role has been expanded to include full Nordic responsibility. Joakim Tingström Nordin's initial focus will be to strengthen ColdZyme's visibility and availability ahead of the upcoming cold season. This includes increased distribution, stronger presence in pharmacies and e-commerce, enhanced product communication, and a more data-driven approach to ratings, reviews, and sampling.
Reported Earnings • Apr 30First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: kr11.4m (down 6.8% from 1Q 2025). Net loss: kr13.5m (loss narrowed 25% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Apr 07Senior Director of Marketing & Sales recently sold kr120k worth of stockOn the 31st of March, Anna Soderlund sold around 40k shares on-market at roughly kr3.00 per share. This transaction amounted to 67% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr461k more than they sold in the last 12 months.
Reported Earnings • Feb 19Full year 2025 earnings released: kr0.21 loss per share (vs kr0.28 loss in FY 2024)Full year 2025 results: kr0.21 loss per share (improved from kr0.28 loss in FY 2024). Revenue: kr53.9m (up 18% from FY 2024). Net loss: kr51.9m (loss narrowed 2.4% from FY 2024). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
お知らせ • Feb 19Enzymatica AB (publ), Annual General Meeting, May 07, 2026Enzymatica AB (publ), Annual General Meeting, May 07, 2026, at 14:30 W. Europe Standard Time. Location: lund. Sweden
New Risk • Feb 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr62m free cash flow). Earnings have declined by 14% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (kr449.1m market cap, or US$49.9m).
分析記事 • Dec 20Will Enzymatica (STO:ENZY) Spend Its Cash Wisely?There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
お知らせ • Dec 13Enzymatica AB (Publ) Announces CFO ChangesEnzymatica AB (publ) announced the appointment of Kristina Rylander as Acting CFO during a transition period in the spring of 2026. She will assume the role on 1 March 2026, following the departure of the current CFO, Therese Filmersson, as previously communicated. Kristina will be responsible for Enzymatica's finance function until Holger Lembrér assumes his position as the new permanent CFO, no later than 13 April 2026. Kristina Rylander has, for an extended period, served as a consultant to Enzymatica, which has provided her with insight into the company's operations and processes. In her role as Acting CFO, she will ensure continuity in Enzymatica's financial reporting, internal processes, and ongoing projects.
Reported Earnings • Nov 02Third quarter 2025 earnings released: kr0.035 loss per share (vs kr0.039 loss in 3Q 2024)Third quarter 2025 results: kr0.035 loss per share. Revenue: kr15.0m (up 19% from 3Q 2024). Net loss: kr8.40m (loss widened 16% from 3Q 2024).
お知らせ • Oct 14Enzymatica Expands the ColdZyme Range with A New Flavor - EucalyptusEnzymatica expands the ColdZyme range with a new flavour - Eucalyptus. The new flavour offers the same barrier technology and clinically proven benefit against common cold viruses, now with a fresh and cooling taste experience. Like other products in the series, ColdZyme Eucalyptus creates a protective barrier in the throat that helps reduce the viral load, shorten the duration of a cold, and relieve symptoms. The ColdZyme range previously included menthol and strawberry flavours - with Eucalyptus now introduced as a fresh, cooling alternative. The launch of ColdZymeEucalyptus will take place in October in Sweden. The product will be available in pharmacies and online. ColdZyme has been shown in peer-reviewed studies to reduce viral load by up to 94% and shorten the duration of a cold by an average of 40%.
お知らせ • Oct 13Enzymatica AB (Publ) Appoints Holger Lembrér as CFO, Effective April 2026Enzymatica AB (publ) has appointed Holger Lembrér as new Chief Financial Officer (CFO). He will assume the position no later than April 2026 and will be part of the company's executive management team. Holger Lembrér brings extensive experience as CFO and finance executive from international and publicly listed companies, primarily within the MedTech, Pharma and industrial sectors. He most recently served as CFO at Boule Diagnostics, where he held overall responsibility for the Group's finance function. Prior to that, Holger was CFO at Oncopeptides and held several senior positions within ASSA ABLOY, including CFO for the Senior Care business area and Investor Relations Officer at Group level. He began his career as an auditor at EY.
お知らせ • Oct 03+ 2 more updatesEnzymatica AB (publ) to Report First Half, 2026 Results on Jul 16, 2026Enzymatica AB (publ) announced that they will report first half, 2026 results on Jul 16, 2026
Recent Insider Transactions • Sep 22Director recently bought kr544k worth of stockOn the 18th of September, Mats Andersson bought around 230k shares on-market at roughly kr2.36 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr970k more in shares than they have sold in the last 12 months.
お知らせ • Aug 22Enzymatica AB (Publ) Appoints Claus Egstrand as Member of Board of DirectorsEnzymatica AB (publ) on 22 August 2025 held an Extraordinary General Meeting approved Claus Egstrand was elected as an ordinary member of the Board of Directors for the period until the end of the next Annual General Meeting.
お知らせ • Aug 13Enzymatica AB (Publ) Announces Chief Executive Officer ChangesThe Board of Directors of Enzymatica AB (publ) has appointed Sana Alajmovic as the new Chief Executive Officer. She succeeds Claus Egstrand, who has announced that he is stepping down from his operational role, but he will be proposed to join the company's Board of Directors in order to ensure continuity. Sana Alajmovic is the co-founder and current CEO of Sigrid Therapeutics. She brings extensive experience from business development and leadership within the life science sector, with a strong track record in commercializing research and developing strategic partnerships with international pharmaceutical and consumer health companies. Known for her strategic thinking and dynamic, empathetic leadership, she has established herself as a pioneer in the industry. Sana Alajmovic has received several awards for her entrepreneurship and leadership, including Sweden's Most Important Female Founder by Dagens Industri in 2021 and Female Leader of the Future by Ledarna in both 2020 and 2021. She has also been named one of the world's top life science innovators under the age of 40. Sana Alajmovic will assume her new role no later than 31 January 2026.
Reported Earnings • Jul 18Second quarter 2025 earnings released: kr0.06 loss per share (vs kr0.08 loss in 2Q 2024)Second quarter 2025 results: kr0.06 loss per share. Revenue: kr8.28m (up 29% from 2Q 2024). Net loss: kr14.5m (loss widened 4.8% from 2Q 2024).
分析記事 • Jul 01Is Enzymatica (STO:ENZY) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
お知らせ • Jun 30Enzymatica AB (Publ) Announces Step Down of Therese Filmersson as CFOEnzymatica AB (publ) announced that the company's Chief Financial Officer (CFO), Therese Filmersson, has decided to leave her position. The decision has been made in mutual agreement between Therese Filmersson and the company's Board of Directors. Therese Filmersson will remain in her role during the notice period to ensure a smooth transition. The recruitment process to find her successor has been initiated.
お知らせ • Jun 26+ 1 more updateEnzymatica AB (publ) Announces Appointment of Claus Egstrand to the BoardThe CEO of Enzymatica AB, Claus Egstrand, is stepping down from his role and will join the company's Board of Directors. Recruitment of a new CEO has begun. The change will ensure long-term stability in the company's leadership as it prepares for international expansion. Following the publication of the strong research results for ColdZyme in The Journal of Physiology in February this year, efforts have intensified to sign international distribution agreements. In order to ensure longer term continuity in these discussions and partnerships, Claus Egstrand has decided to step down from his position as CEO of Enzymatica. The Nomination Committee of Enzymatica intends to propose Claus Egstrand as a new member of the company's Board of Directors. The proposal will be presented at an Extraordinary General Meeting and it already has the support of a clear majority of shareholders.
お知らせ • Jun 21Enzymatica AB (publ) to Report Fiscal Year 2025 Final Results on Apr 14, 2026Enzymatica AB (publ) announced that they will report fiscal year 2025 final results on Apr 14, 2026
New Risk • May 02New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr62m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr62m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr48m revenue, or US$5.0m). Market cap is less than US$100m (kr708.8m market cap, or US$72.7m).
Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Moa Fransson was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 16Full year 2024 earnings released: kr0.28 loss per share (vs kr0.30 loss in FY 2023)Full year 2024 results: kr0.28 loss per share. Revenue: kr45.6m (down 11% from FY 2023). Net loss: kr53.2m (loss widened 6.9% from FY 2023).
お知らせ • Apr 03Enzymatica AB (publ), Annual General Meeting, May 07, 2025Enzymatica AB (publ), Annual General Meeting, May 07, 2025, at 14:30 W. Europe Standard Time. Location: elite hotel ideon, scheelevagen 27, lund Sweden
New Risk • Feb 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr61m free cash flow). Earnings have declined by 18% per year over the past 5 years. Shareholders have been substantially diluted in the past year (48% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (kr46m revenue, or US$4.2m). Market cap is less than US$100m (kr356.8m market cap, or US$33.3m).
Reported Earnings • Feb 19Full year 2024 earnings released: kr0.25 loss per share (vs kr0.30 loss in FY 2023)Full year 2024 results: kr0.25 loss per share. Revenue: kr45.6m (down 11% from FY 2023). Net loss: kr53.2m (loss widened 6.9% from FY 2023).
お知らせ • Feb 18Enzymatica AB (publ) to Report Fiscal Year 2025 Results on Feb 18, 2026Enzymatica AB (publ) announced that they will report fiscal year 2025 results on Feb 18, 2026
New Risk • Jan 23New major risk - Revenue and earnings growthEarnings have declined by 17% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr44m revenue, or US$4.0m). Market cap is less than US$100m (kr321.5m market cap, or US$29.2m).
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr52m net loss in 2 years). Revenue is less than US$5m (kr44m revenue, or US$4.0m). Market cap is less than US$100m (kr353.9m market cap, or US$31.7m).
お知らせ • Jan 09Enzymatica AB Appoints Anna Söderlund as Senior Director Marketing & SalesEnzymatica AB (publ) announced that Anna Söderlund has joined as the new Senior Director Marketing & Sales. With over 25 years of experience in the Life Science industry, where she has held leading roles at global companies such as Pfizer and MSD, Anna brings solid expertise to the company. Anna Söderlund holds a Master of Science in Economics from Linköping University and has previously successfully worked in key roles in marketing, sales and business development. The recruitment of Anna Söderlund strengthens Enzymatica's commitment to further expand and establish itself as a leading player in its segment. Anna Söderlund has taken up her position and is part of Enzymatica's Group Management.
Recent Insider Transactions • Nov 17Independent Director recently bought kr93k worth of stockOn the 11th of November, Louise Nicolin bought around 51k shares on-market at roughly kr1.84 per share. This transaction amounted to 51% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr117k. Despite this recent purchase, insiders have collectively sold kr1.4m more in shares than they bought in the last 12 months.
Reported Earnings • Nov 08Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: kr12.6m (down 5.3% from 3Q 2023). Net loss: kr7.25m (loss narrowed 22% from 3Q 2023). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 32% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.
お知らせ • Nov 07+ 3 more updatesEnzymatica AB (publ) to Report Fiscal Year 2024 Results on Apr 10, 2025Enzymatica AB (publ) announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on Apr 10, 2025
Recent Insider Transactions • Sep 25Independent Chairman recently bought kr117k worth of stockOn the 16th of September, Bengt Baron bought around 45k shares on-market at roughly kr2.60 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Bengt has been a buyer over the last 12 months, purchasing a net total of kr681k worth in shares.
Recent Insider Transactions • Sep 23Independent Chairman recently bought kr117k worth of stockOn the 16th of September, Bengt Baron bought around 45k shares on-market at roughly kr2.60 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Bengt has been a buyer over the last 12 months, purchasing a net total of kr681k worth in shares.
お知らせ • Aug 17Enzymatica AB (publ) Announces Final Results from Independent Clinical Study of Coldzyme Show Duration of Illness Lowered by Approximately 5 DaysEnzymatica AB announced that the University of Kent has published final results for the Primary Endpoint from the now completed double-blind, placebo-controlled, randomized trial. The study now completed is an independent, investigator initiated in vivo study led by Glen Davison, professor of sports and exercise science and researcher in exercise immunology at the University of Kent, in England. ColdZyme directly forms a physical barrier in the mouth and throat that coats, moisturizes and protects the oral cavity and throat, trapping viruses and inactivating and inhibiting the ability of trapped viruses to infect cells and reproduce. The over-the-counter mouth spray has been certified according to the EU regulation MDR (class III) by Eurofins, an approved European control body for medical devices. The certification entails stricter requirements for the evidence of clinical validity, safe design and market surveillance. ColdZyme products are now MDR certified with the following expanded intended uses: Treat and relieve cold and flu-like symptoms. and with the following extended product claims: Protects against viruses that cause cold and flu-like infections in the upper respiratory tract. Shortens the duration of cold and flu-like infections of the upper respiratory tract if used at an early stage of the infection. Relieves cold and flu-like symptoms, including sore throat.
New Risk • Aug 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr16m net loss in 2 years). Shareholders have been diluted in the past year (5.6% increase in shares outstanding). Revenue is less than US$5m (kr45m revenue, or US$4.3m). Market cap is less than US$100m (kr324.2m market cap, or US$30.7m).
New Risk • Jul 22New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr56m Forecast net loss in 2 years: kr16m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr16m net loss in 2 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (5.6% increase in shares outstanding). Significant insider selling over the past 3 months (kr645k sold). Revenue is less than US$5m (kr45m revenue, or US$4.2m). Market cap is less than US$100m (kr346.8m market cap, or US$32.5m).
Breakeven Date Change • Jul 22No longer forecast to breakevenThe 2 analysts covering Enzymatica no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr12.3m in 2026. New consensus forecast suggests the company will make a loss of kr46.2m in 2026.
お知らせ • Jul 20Enzymatica AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 131.770487 million.Enzymatica AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 131.770487 million. Security Name: Shares Security Type: Common Stock Securities Offered: 69,352,888 Price\Range: SEK 1.9 Transaction Features: Rights Offering
分析記事 • Jul 20Is Enzymatica (STO:ENZY) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Jul 19Second quarter 2024 earnings released: kr0.08 loss per share (vs kr0.07 loss in 2Q 2023)Second quarter 2024 results: kr0.08 loss per share (further deteriorated from kr0.07 loss in 2Q 2023). Revenue: kr6.43m (down 27% from 2Q 2023). Net loss: kr13.8m (loss widened 20% from 2Q 2023). Revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 38% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.
Recent Insider Transactions • Jun 21Independent Director recently bought kr4.6m worth of stockOn the 13th of June, Gudmundur Palmason bought around 2m shares on-market at roughly kr2.98 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr4.4m more in shares than they have sold in the last 12 months.
Major Estimate Revision • Jun 16Consensus EPS estimates fall by 21%, revenue upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from kr63.2m to kr65.0m. Forecast EPS reduced from -kr0.253 to -kr0.306 per share. Pharmaceuticals industry in Sweden expected to see average net income growth of 21% next year. Consensus price target broadly unchanged at kr4.34. Share price fell 3.5% to kr2.72 over the past week.
お知らせ • Jun 15Enzymatica AB (Publ) Announces Interim Results from Independent Clinical Study of Coldzyme® Show Duration of Illness Lowered by Approximately 5 DaysEnzymatica AB announced that University of Kent has earlier this afternoon published interim results from the ongoing double-blind, placebo-controlled, randomized on the effects of ColdZyme and the product's effect on treating the symptoms and duration of Upper Respiratory Tract Infections (URTI). Interim results have showed that Enzymatica's ColdZyme oral spray reduces the amount of rhinovirus and reduces the number of sick days by approximately five days, with number of sick days being the primary endpoint of the study. The study is an independent, investigator-initiated in vivo study led by Glen Davison, professor of sports and exercise science and researcher in exercise immunology at the University of Kent, in England. Glen Davison researches the effects of training and exercise on the immune system and the body's resistance to infections. The main focus is evaluating products and measures that can help prevent upper respiratory tract infections, such as the common cold. Glen Davison and his research team have been studying the effects of Cold Zyme since 2017 and published the first study four years ago. The study is investigator-initiated, prospective, double-blind, placebo- controlled, and randomized. The study includes roughly 160 athletes in endurance sports, divided into two groups, where one received ColdZyme and the other a placebo. The participants have kept a training diary and filled in a daily questionnaire about symptoms in the upper respiratory tract. When participants experienced symptoms, they took throat samples and began using the mouth spray as instructed. ColdZyme directly forms a physical barrier in the mouth and throat that coats, moisturizes and protects the oral cavity and throat, trapping viruses and inactivating and inhibiting the ability of trapped viruses to infect cells and reproduce. The over-the-counter mouth spray has been certified according to the EU regulation MDR (class III) by Eurofins, an approved European control body for medical devices. The certification entails stricter requirements for the evidence of clinical validity, safe design and market surveillance. ColdZyme products are now MDR certified with the following expanded intended uses: Treat and relieve cold and flu-like symptoms. and with the following extended product claims: Protects against viruses that cause cold and flu-like infections in the upper respiratory tract. Shortens the duration of cold and flu-like infections of the upper respiratory tract if used at an early stage of the infection. Relieves cold and flu-like symptoms, including sore throat.
Major Estimate Revision • May 02Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from kr78.1m to kr65.5m. Forecast losses increased from -kr0.186 to -kr0.262 per share. Pharmaceuticals industry in Sweden expected to see average net income growth of 9.6% next year. Consensus price target down from kr5.02 to kr4.44. Share price fell 6.5% to kr3.03 over the past week.
Breakeven Date Change • May 02Forecast to breakeven in 2026The 2 analysts covering Enzymatica expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 29% per year to 2025. The company is expected to make a profit of kr12.6m in 2026. Average annual earnings growth of 76% is required to achieve expected profit on schedule.
New Risk • Apr 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr36m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr36m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr24m net loss in 2 years). Shareholders have been diluted in the past year (5.6% increase in shares outstanding). Significant insider selling over the past 3 months (kr960k sold). Revenue is less than US$5m (kr47m revenue, or US$4.3m). Market cap is less than US$100m (kr504.5m market cap, or US$46.1m).
Reported Earnings • Apr 26First quarter 2024 earnings released: kr0.11 loss per share (vs kr0.091 loss in 1Q 2023)First quarter 2024 results: kr0.11 loss per share (further deteriorated from kr0.091 loss in 1Q 2023). Revenue: kr9.42m (down 28% from 1Q 2023). Net loss: kr18.9m (loss widened 26% from 1Q 2023). Revenue is forecast to grow 40% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 31% per year, which means it is performing significantly worse than earnings.
New Risk • Apr 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr15m net loss in 3 years). Shareholders have been diluted in the past year (5.6% increase in shares outstanding). Significant insider selling over the past 3 months (kr960k sold). Revenue is less than US$5m (kr51m revenue, or US$4.8m). Market cap is less than US$100m (kr599.9m market cap, or US$56.7m).
Recent Insider Transactions • Mar 29Independent Director recently sold kr60k worth of stockOn the 25th of March, Gudmundur Palmason sold around 19k shares on-market at roughly kr3.14 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth kr900k. Despite this recent sale, insiders have collectively bought kr400k more than they sold in the last 12 months.
お知らせ • Mar 28Enzymatica AB (publ) Announces Composition of Nomination CommitteeEnzymatica AB (publ) announced the nomination committee, in respect of the annual general meeting 2024, has been comprised of Mats Andersson (Abanico Invest AB as well as private holdings), Håkan Roos (Roosgruppen AB), Björn Algkvist (Fibonacci Growth Capital AB), Guðmundur Pálmason (Fortus hf.) and the chairman of the board, Bengt Baron. Björn Algkvist served as chairman of the Nomination Committee.
New Risk • Mar 26New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: kr50m Forecast net loss in 3 years: kr15m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr15m net loss in 3 years). Significant insider selling over the past 3 months (kr900k sold). Revenue is less than US$5m (kr51m revenue, or US$4.8m). Market cap is less than US$100m (kr501.0m market cap, or US$47.5m).
Breakeven Date Change • Mar 26No longer forecast to breakevenThe 2 analysts covering Enzymatica no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of kr22.6m in 2025. New consensus forecast suggests the company will make a loss of kr849.6k in 2025.
お知らせ • Mar 15Enzymatica AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 27.37614 million.Enzymatica AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 27.37614 million. Security Name: Shares Security Type: Common Stock Securities Offered: 9,125,380 Price\Range: SEK 3 Transaction Features: Rights Offering
Recent Insider Transactions • Mar 03Independent Director recently sold kr900k worth of stockOn the 23rd of February, Gudmundur Palmason sold around 300k shares on-market at roughly kr3.00 per share. This transaction amounted to 3.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr390k more than they bought in the last 12 months.
New Risk • Feb 19New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr41m free cash flow). Earnings have declined by 13% per year over the past 5 years. Minor Risks Revenue is less than US$5m (kr51m revenue, or US$4.9m). Market cap is less than US$100m (kr500.2m market cap, or US$48.0m).
Reported Earnings • Feb 18Full year 2023 earnings released: kr0.30 loss per share (vs kr0.45 loss in FY 2022)Full year 2023 results: kr0.30 loss per share (improved from kr0.45 loss in FY 2022). Revenue: kr50.9m (up 4.0% from FY 2022). Net loss: kr49.7m (loss narrowed 28% from FY 2022). Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 16Enzymatica AB (publ) to Report Fiscal Year 2023 Final Results on Apr 09, 2024Enzymatica AB (publ) announced that they will report fiscal year 2023 final results at 9:00 AM, Central European Standard Time on Apr 09, 2024
New Risk • Feb 08New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr65m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr65m free cash flow). Minor Risks Revenue is less than US$5m (kr52m revenue, or US$4.9m). Market cap is less than US$100m (kr553.5m market cap, or US$52.8m).
お知らせ • Dec 07+ 4 more updatesEnzymatica AB (publ) to Report Q1, 2024 Results on Apr 25, 2024Enzymatica AB (publ) announced that they will report Q1, 2024 results on Apr 25, 2024
Major Estimate Revision • Nov 14Consensus revenue estimates decrease by 30%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from kr76.3m to kr53.0m. EPS estimate unchanged from -kr0.15 per share at last update. Pharmaceuticals industry in Sweden expected to see average net income growth of 27% next year. Consensus price target down from kr5.63 to kr5.15. Share price fell 2.1% to kr3.32 over the past week.
Reported Earnings • Nov 08Third quarter 2023 earnings released: kr0.056 loss per share (vs kr0.085 loss in 3Q 2022)Third quarter 2023 results: kr0.056 loss per share (improved from kr0.085 loss in 3Q 2022). Revenue: kr13.3m (down 28% from 3Q 2022). Net loss: kr9.24m (loss narrowed 29% from 3Q 2022). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.
Recent Insider Transactions • Oct 02Independent Chairman recently bought kr564k worth of stockOn the 27th of September, Bengt Baron bought around 190k shares on-market at roughly kr2.97 per share. This transaction amounted to 5.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Bengt has been a buyer over the last 12 months, purchasing a net total of kr1.6m worth in shares.
お知らせ • Sep 22Enzymatica AB (publ) Announces Interim Report from Clinical Study: ColdZyme Significantly Reduces Rhinovirus Viral Load and Symptoms of Sore ThroatEnzymatica AB (publ) announced that the first results from an ongoing independent clinical study at the University of Kent, UK, show that ColdZyme® significantly reduces the viral load of rhinovirus, the predominant cause of the common cold. Additionally, participants who used ColdZyme experienced significantly less severe sore throat symptoms than those who used placebo. The researchers are assessing the efficacy of ColdZyme mouth spray on upper respiratory tract infection (URTI) parameters, including viral load, in a randomized, double-blind, and placebo-controlled trial, under free-living conditions in endurance athletes (e.g. runners, cyclists, triathletes). The final study is expected to be published in 2024. The interim results have been submitted for presentation at a scientific conference, and are currently under review, hopefully for presentation early in 2024. The trial is investigator initiated, prospective, double-blind, placebo-controlled, and randomized. So far, it comprises 51 endurance athletes divided into two groups, one which received ColdZyme and the other placebo. Participants kept a training log and filled out a daily questionnaire on upper respiratory tract infection symptoms. When participants experienced symptoms, they were instructed to take self-swabs from their throat and start using the mouth spray according to instructions. The trial builds on a previous study in 2020 by the same research team, showing that ColdZyme reduces the duration and symptoms of common cold in endurance athletes. ColdZyme is a prescription free mouth spray that is sold in more than 30 markets on four continents. It is also marketed under brand names such as ViruProtect®, Physiomer®, Bisolviral® and ADerogyl®.
お知らせ • Aug 23Enzymatica AB (publ) Announces New StudyEnzymatica AB (publ) announced new study: ColdZyme breaks the infection cycle, limiting the spread of viruses to more cells. The researchers believe that ColdZyme would have the same effect on other respiratory viruses. ColdZyme mouth spray is sold in more than 30 markets on four continents, also under brand names such as ViruProtect, Bisolviral and ADerogyl. Previous studies have shown how application of ColdZyme before infection blocks viruses from sticking to human cells. The new study shows that ColdZyme also reduces viral load and the virus's ability to spread in cell cultures that were already infected with virus (influenza A, H3N2). The research from the Medical University of Innsbruck shows a more than 99% lower viral load after only three treatments with ColdZyme, compared to infected cells that were treated with salt solution.
分析記事 • Jul 22Is Enzymatica (STO:ENZY) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Jul 19Second quarter 2023 earnings released: kr0.07 loss per share (vs kr0.10 loss in 2Q 2022)Second quarter 2023 results: kr0.07 loss per share (improved from kr0.10 loss in 2Q 2022). Revenue: kr8.76m (down 8.9% from 2Q 2022). Net loss: kr11.5m (loss narrowed 25% from 2Q 2022). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has fallen by 47% per year, which means it is performing significantly worse than earnings.
Recent Insider Transactions • Jun 24Independent Director recently bought kr157k worth of stockOn the 16th of June, Louise Nicolin bought around 57k shares on-market at roughly kr2.75 per share. This transaction increased Louise's direct individual holding by 1x at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr414k. Despite this recent purchase, insiders have collectively sold kr575k more in shares than they bought in the last 12 months.
Recent Insider Transactions • Jun 22Independent Director recently bought kr157k worth of stockOn the 16th of June, Louise Nicolin bought around 57k shares on-market at roughly kr2.75 per share. This transaction increased Louise's direct individual holding by 1x at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth kr414k. Despite this recent purchase, insiders have collectively sold kr575k more in shares than they bought in the last 12 months.
Recent Insider Transactions • May 04Independent Chairman recently bought kr414k worth of stockOn the 28th of April, Bengt Baron bought around 160k shares on-market at roughly kr2.59 per share. This transaction amounted to 8.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth kr600k. Bengt has been a buyer over the last 12 months, purchasing a net total of kr1.0m worth in shares.
Reported Earnings • Apr 30First quarter 2023 earnings released: kr0.091 loss per share (vs kr0.12 loss in 1Q 2022)First quarter 2023 results: kr0.091 loss per share (improved from kr0.12 loss in 1Q 2022). Revenue: kr13.0m (up 213% from 1Q 2022). Net loss: kr14.9m (loss narrowed 17% from 1Q 2022). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 32% per year, which means it has not declined as severely as earnings.
Recent Insider Transactions • Mar 15Independent Director recently sold kr1.5m worth of stockOn the 9th of March, Gudmundur Palmason sold around 500k shares on-market at roughly kr3.00 per share. This transaction amounted to 5.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of kr1.2m more than they bought in the last 12 months.
Breakeven Date Change • Mar 12Forecast to breakeven in 2025The 2 analysts covering Enzymatica expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 56% per year to 2024. The company is expected to make a profit of kr8.01m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule.
Major Estimate Revision • Feb 24Consensus revenue estimates decrease by 15%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from kr82.3m to kr69.9m. EPS estimate unchanged from -kr0.23 per share at last update. Pharmaceuticals industry in Sweden expected to see average net income growth of 14% next year. Consensus price target down from kr5.99 to kr5.71. Share price fell 16% to kr2.78 over the past week.
Reported Earnings • Feb 19Full year 2022 earnings released: kr0.45 loss per share (vs kr0.31 loss in FY 2021)Full year 2022 results: kr0.45 loss per share (further deteriorated from kr0.31 loss in FY 2021). Revenue: kr48.9m (down 14% from FY 2021). Net loss: kr68.7m (loss widened 51% from FY 2021). Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 18Enzymatica AB (publ) to Report Fiscal Year 2023 Results on Feb 16, 2024Enzymatica AB (publ) announced that they will report fiscal year 2023 results on Feb 16, 2024
分析記事 • Feb 18Is Enzymatica (STO:ENZY) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Jan 19+ 3 more updatesEnzymatica AB (publ) to Report Nine Months, 2023 Results on Nov 07, 2023Enzymatica AB (publ) announced that they will report nine months, 2023 results on Nov 07, 2023
Breakeven Date Change • Nov 18No longer forecast to breakevenThe analyst covering Enzymatica no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr10.4m in 2023. New forecast suggests the company will make a loss of kr995.4k in 2024.
Reported Earnings • Nov 03Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: kr18.5m (up 20% from 3Q 2021). Net loss: kr13.1m (loss widened 114% from 3Q 2021). Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 30% growth forecast for the Pharmaceuticals industry in Sweden.
Major Estimate Revision • Jul 26Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from kr99.7m to kr86.1m. EPS estimate increased from -kr0.23 to -kr0.21 per share. Pharmaceuticals industry in Sweden expected to see average net income growth of 4.4% next year. Consensus price target down from kr9.64 to kr7.40. Share price was steady at kr5.50 over the past week.
Reported Earnings • Jul 19Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr9.62m (up 57% from 2Q 2021). Net loss: kr15.4m (loss narrowed 22% from 2Q 2021). Over the next year, revenue is forecast to grow 188%, compared to a 97% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 5% per year.
Breakeven Date Change • May 06Forecast breakeven date moved forward to 2022The 2 analysts covering Enzymatica previously expected the company to break even in 2023. New consensus forecast suggests the company will make a profit of kr8.50m in 2022. Earnings growth of 97% is required to achieve expected profit on schedule.